Sugi Predict

Sugi Predict / Compounds / SCHEMBL2850367

SCHEMBL2850367

SCHEMBL2850367

O=C(O)c1cnn(-c2ccc(F)cc2)c1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALKBH2 Q6NS38 2/20 0.72
▸ HPGDS O60760 1/20 0.72
▸ ALKBH1 Q13686 3/20 0.56
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ EGLN1 Q9GZT9 3/20 0.53
▸ BCL2L1 Q07817 1/20 0.48
▸ BAD Q92934 1/20 0.48
▸ HSD11B1 P28845 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ HPGD P15428 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ HTT P42858 1/20 0.48
▸ NFKB2 Q00653 1/20 0.48
▸ RELA Q04206 1/20 0.48
▸ PTGDR2 Q9Y5Y4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL180639 0.86 BCL2L1 (0.59) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL3916180 0.85 MAP4K4 (0.55) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL30882345 0.85 HPGDS (0.51) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL70281 0.84 ALKBH2 (1.00) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL2856651 0.83 ALKBH2 (0.72) ALKBH2HPGDSNPC1RAB9AEGLN1
SCHEMBL2860260 0.83 ALKBH2 (0.72) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL27680338 0.83 ALKBH2 (0.72) ALKBH2HPGDSALKBH1NPC1RAB9A
SCHEMBL2852078 0.83 ALKBH2 (0.72) ALKBH2HPGDSNPC1RAB9AEGLN1
SCHEMBL30882479 0.82 HPGDS (0.49) ALKBH2HPGDSALKBH1NPC1RAB9A
Hydrochloric Acid SCHEMBL16467067 0.81 ALKBH2 (0.70) ALKBH2HPGDSALKBH1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451160-B1 PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN ICAGEN INC (US) 2010-01-13 — — EP claimed
US-20080242671-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2008-10-02 — — US claimed
CN-119661538-A Pyrazolo [3,4-d ] pyrimidine-4-ketone derivative and application thereof 中国科学院精密测量科学与技术创新研究院 2025-03-21 — — CN disclosed
CN-117903077-B Dihydrooxadiazinone compound and application thereof 上海超阳药业有限公司 2024-09-03 — — CN disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 — — US disclosed
CN-117903077-A Dihydrooxadiazinon compound and application thereof 上海超阳药业有限公司 2024-04-19 — — CN disclosed
EP-4149945-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2023-03-22 — — EP disclosed
CN-115551864-A Substituted tricyclic amides, analogs thereof, and methods of using the same 爱彼特生物制药公司 2022-12-30 — — CN disclosed
EP-3787619-B1 SERPIN INHIBITORS FOR THE TREATMENT OF PRION AND PRION-LIKE DISEASES SCUOLA INT SUPERIORE DI STUDI AVANZATI SISSA (IT) 2022-05-11 — — EP disclosed
US-7223782-B2 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2007-05-29 — — US disclosed
US-7015218-B1 Amide compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-03-21 — — US disclosed
CN-1230421-C Amide compound and pharmaceutical use thereof MITSUBISHI CHEM CORP (JP) 2005-12-07 — — CN disclosed
US-20050049237-A1 Pyrazole-amides and -sulfonamides ICAGEN, INC. (US) 2005-03-03 — — US disclosed
EP-1176140-B1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2004-12-29 — — EP disclosed
US-20040248887-A1 Inhibitors of cathepsin S IRM LLC (BM) 2004-12-09 — — US disclosed
WO-2004084843-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-10-07 — — WO disclosed
CN-1346348-A Amide compound and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL (JP) 2002-04-24 — — CN disclosed
EP-1176140-A1 AMIDE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2002-01-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248887-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ ALKBH2 4861/4885HPGDS 615/4885ALKBH1 4844/4885
US-20050049237-A1 Pyrazole-amides and -sulfonamides SCN3A, TRPV3, HCN3 ALKBH2 4440/4885HPGDS 1109/4885ALKBH1 4277/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 ALKBH2 396/4885HPGDS 869/4885ALKBH1 92/4885
US-20080242671-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ ALKBH2 4861/4885HPGDS 615/4885ALKBH1 4844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.